Regeneron Pharmaceuticals - Articles and news items

Kevzara

FDA accepts Sanofi and Regeneron’s biologics license resubmission

Industry news / 2 May 2017 / Niamh Marriott, Junior Editor

The FDA has accepted the resubmission of Sanofi and Regeneron Pharmaceuticals’ Biologics License Application for Kevzara (sarilumab)…

Sanofi and Regeneron receive CHMP positive opinion for rheumatoid arthritis treatment

Industry news / 28 April 2017 / Niamh Marriott, Junior Editor

The European Medicine Agency’s CHMP has adopted a positive opinion for the marketing authorisation of Sanofi and Regeneron Pharmaceuticals’ Kevzara…

2017 Pipelines: Drugs to watch

Blog, Z Homepage promo / 12 April 2017 / Alexandra Kibble, Senior Editor, Clarivate Analytics Cortellis

The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of >$900 billion by 2021…

FDA approves Sanofi and Regeneron’s new eczema drug

Industry news / 3 April 2017 / Niamh Marriott, Junior Editor

The US Food and Drug Administration (FDA) approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis)…

patent litigation

Amgen vs. Sanofi – appeals court suspend patent injunction

Industry news / 9 February 2017 / Niamh Marriott, Digital Editor

“It is our longstanding position that Amgen’s asserted patent claims are invalid and we look forward to moving forward with the appeal process.”

application

EMA to review Sanofi and Regeneron’s dermatitis drug application

Industry news / 13 December 2016 / Niamh Louise Marriott, Digital Editor

The European Medicines Agency (EMA) has accepted for review the marketing authorisation application for Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. The investigational biologic therapy Dupixent inhibits signaling of IL-4 and IL-13, two key cytokines required for the type 2 (including Th2) […]

Success for Regeneron and Sanofi’s atopic dermatitis trial

Industry news / 5 October 2016 / Niamh Louise Marriott, Digital Content Producer

Two placebo-controlled Phase 3 trials, evaluating dupixent in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD)…

Success for Sanofi and Regeneron’s LDL cholesterol trial

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

The trial showed adding praluent to existing therapy reduced LDL cholesterol by approximately 50% from baseline, compared to 2% increase for placebo…

cimzia arthritis x-ray hands bones

Sanofi and Regeneron announce EMA acceptance for review of Marketing Authorisation Application for sarilumab

Industry news / 1 August 2016 / Sanofi / Regeneron Pharmaceuticals, Inc.

Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis…

Dupilumab + TCS superior to TCS alone in treating atopic dermatitis

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

Sanofi and Regeneron have announced that a Phase III study evaluating dupilumab in atopic dermatitis met its primary and key secondary endpoints…

Positive topline results from two Phase III dupilumab studies

Industry news / 1 April 2016 / Victoria White

The two Phase III studies evaluated investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis…

Regeneron and Bayer team up to develop a novel therapy for eye diseases

Industry news / 24 March 2016 / Victoria White

Regeneron and Bayer are to develop a combination therapy of the Ang2 antibody nesvacumab and the VEGF trap aflibercept for the treatment of eye diseases…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+